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positive PCR results were suspected of
harboring B19 infection on the basis of
clinical assessments [1]. Yet, retrospective
review showed that the B19-associated cy-
topenias significantly prolonged periods
of unwanted interruption of chemother-
apy, necessitated more blood transfusions,
and compelled more bone marrow ex-
aminations. Our purpose here was to ex-
tend those findings by studying children
with other malignancies or hematological
disorders.
During a period of 5.5 years, exami-
nations of bone marrow for proven or
suspected malignant disorders were sup-
plemented with screening for parvovirus
B19 DNA with a qualitative PCR. Positive
samples were then analyzed with the
quantitative PCR [1]. Informed consent
to participate in the study was obtained
from the children or their guardians. The
study was approved by the ethical com-
mittee at Karolinska Institutet (Stock-
holm, Sweden).
A total of 229 bone marrow samples
from 123 children who underwent bone
marrow examinations were collected.
Overall, 9 (7%) of 123 patients were pos-
itive for B19 DNA, and 8 of those 9 had
test results positive for B19 DNA at the
time of diagnosis of the underlying dis-
ease. No additional underlying immuno-
deficiency or previous blood transfusion
was recorded. Consecutive samples were
available from 4 of the B19 DNA–positive
patients (2–7 samples per patient), and the
outcomes were recorded for 5–32 months.
B19 DNA was, in one instance, persistently
detected for 124 months after diagnosis,
and viral loads consisted of up to
copies/mL. According to a re-78.7 10
view of medical records, none of the B19
infections were suspected on clinical
grounds, and the infections were not clus-
tered during any given time of year or
epidemic period. Serum samples that had
been collected at the time of the first bone
marrow sample collection were available
from 27 of these children. Of these 27 chil-
dren, 13 (48%) were B19 immunoglobulin
G positive, whereas only 1 was B19 im-
munoglobulin M positive. During the 6
months after diagnosis of the underlying
disorder, all but 2 of the B19 DNA–pos-
itive patients experienced multiple epi-
sodes of fever and severe long-standing
cytopenias that required multiple blood
transfusions (range, 5–60 transfusions).
Except for studies involving children
with ALL, little information is available on
the influence and persistence of B19 in-
fection among children with malignancies
[1–6]. In the present study, 7% of children
with malignant or hematological disorders
were found to be B19 DNA positive and
this infection likely contributed to some
of the severe cytopenic periods observed.
Viral load was detected in high titers, and
some children had prolonged periods of
detectable B19 DNA. Owing to the mul-
tiplicity of these underlying diagnoses, no
statistical comparison was possible for
B19-infected versus uninfected individu-
als, as was done in our previous study in-
volving children with ALL [4]. However,
that study served as the basis for our con-
tention that screening with PCR for B19
DNA in bone marrow samples is clinically
important for all children with malignan-
cies, not only for early detection and treat-
ment of the infection but also for limiting
the effects of associated complications. Fu-
ture studies will hopefully clarify the clin-
ical relevance of viral load levels in differ-
ent patient categories, at which levels to
initiate antiviral treatment, and whether
analyses of serum samples is as sensitive
as analysis of bone marrow samples. Con-
sidering the notable number of B19 DNA–
positive children in our relatively small but
significant study, we suggest that quanti-
tative PCR testing is a useful differential
diagnostic tool in these patient categories.
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Oseltamivir Dosing
in Children Undergoing
Hemodialysis
To the Editor—With the advent of the
new influenza A (H1N1) virus, the need
for antiviral treatment has increased, es-
pecially in vulnerable patients, such as pa-
tients undergoing dialysis [1]. For adult
patients, Robson et al [2] have provided
a guideline for dosing of oseltamivir,
whereas for children undergoing dialysis,
such data are lacking.
On the basis of data from Robson et al
[2], we formulated a dosing schedule for
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Table 1. Characteristics of 3 Children undergoing Hemodialysis (HD) and Treated with Oseltamivir
Patient
Age,
years Sex
Body
weight, kg Diagnosis
Endogenous
creatinine
clearance,
mL/min/1.73 m2 HD treatment
Oseltamivir
carboxylate
plasma concentration
before HD session,
ng/mL
Oseltamivir
carboxylate
plasma concentration
after HD session,
ng/mL
A 3 M 15 Denys-Drash syndrome,
bilateral nephrectomy
0 For 3 h 4 times per week; Fresenius
F4HPS dialyser; effective blood-
flow, 100 mL/min
660 133
B 6 M 24 Posterior urethral valves 5 For 3 h 3 times per week; Fresenius
FX5 dialyser; effective bloodflow,
100 mL/min
207 37.3
C 11 F 34 Interstitial nephritis 2 For 4 h 3 times per week and for 3
h 1 time per week; Fresenius FX5
dialyser; bloodflow, 225 mL/min
419 60.7
children undergoing intermittent hemo-
dialysis (HD). Contrary to the recom-
mendation from Robson et al [2] to dose
after alternate HD sessions [2], we suggest
to dose oseltamivir in children (age, 11
year) after each HD session (7.5 mg for
children weighing15 kg, 10 mg for chil-
dren weighing 16–23 kg, 15 mg for chil-
dren weighing 24–40 kg, and 30 mg for
children weighing 140 kg).
We have based this recommendation on
2 main arguments. First, dosing after al-
ternate dialysis sessions leads to a low
plasma concentration of oseltamivir car-
boxylate from the first HD session after
the dosing until the next dosing, which is
a period of ∼48 h. Even though the total
area under the curve is appropriate, the
plasma concentration during this latter 48
h may be suboptimal. Second, safety anal-
ysis of oseltamivir has shown that high
plasma concentrations are generally well
tolerated [3] and may even be more ef-
fective than low concentrations [4].
To test our dosing schedule, plasma
concentrations of oseltamivir carboxylate
were measured using a validated liquid
chromatography tandem mass spectrom-
etry (LC-MS/MS) method (PRA Inter-
national) in 3 children undergoing HD
with suspected H1N1 infection. Blood
samples, obtained from patients after a
median of 2 days treatment, were taken
just before and after an HD session to
define extracorporeal elimination.
Results from the analysis are presented
in Table 1. All patients recovered well, and
none of the patients experienced any ad-
verse effects as a result of the treatment.
Our data show that plasma concentrations
are attained at the lower end of an adult
reference population [2] and that extra-
corporeal elimination is higher than ex-
pected (180%).
We present the first data on oseltamivir
dosing in children undergoing HD [5].
These data illustrate the appropriateness
of our dosing schedule, and the high ex-
tracorporeal elimination indicates the
need to supply a dose of oseltamivir after
each HD session to prevent subsequent
subtherapeutic exposure [2, 5]. Obviously,
3 patients are not enough to provide ad-
equate evidence for our schedule, but in
the clinical setting, we are confronted with
children undergoing HD who need ade-
quate and safe oseltamivir treatment. This
forces us to define a dosing schedule on
the basis of sparse data. We hope that more
data will become available to define the
best oseltamivir dosing schedule for this
vulnerable patient cohort.
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Timely Administration
of Antivirals for Pandemic
(H1N1) 2009 Influenza
To the Editor—As part of a study on
pandemic (H1N1) 2009 in patients hos-
pitalized at our institution from 1 May
through 30 June 2009, we evaluated an-
tiviral prescribing practice and its timeli-
ness. All study patients had positive test
results for pandemic (H1N1) 2009 with
use of an in-house reverse transcription
polymerase chain reaction (RT-PCR), and
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